Special Issue

Pharmacoepidemiology and Addiction—2nd Edition

Message from the Guest Editor

This Special Issue aims to update the current or shifting trends in substance use, the identification of novel psychoactive substances, the development of novel pharmacologic treatments for mono- or polysubstance use, outcome research for currently established pharmacologic treatments of addiction, the integration of pharmacologic treatments for comorbid conditions into addiction medicine and the development of pharmacologic interventions for drug overdose or other adverse outcomes. This issue will accept original research articles, review articles, commentaries, letters or other materials facilitating the understanding of addiction through pharmacoepidemiology.

Guest Editor

Dr. Matthew Ellis

Department of Psychiatry, Washington University in St. Louis, School of Medicine, St.Louis, MO, USA

Deadline for manuscript submissions

31 May 2025



Pharmacoepidemiology

an Open Access Journal by MDPI



mdpi.com/si/202378

Pharmacoepidemiology MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmacoepidemiology@mdpi.com

mdpi.com/journal/ pharmacoepidemiology





Pharmacoepidemiolog

an Open Access Journal by MDPI



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Carlotta Franchi

Department of Health Policy, Head of Laboratory of Pharmacoepidemiology and Human Nutrition, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.5 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the second half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

